All In MedTech

Device Trial Radar · NCT04010266

RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use

Safety and Effectiveness of Virtual Reality Utilizing RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use

Last checked: Nov 19, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

63

Actual

Start

Mar 1, 2021

Primary completion

Aug 31, 2022

Study completion Aug 31, 2023

Sponsor

Lead sponsor
AppliedVR Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Geisinger Clinic; National Institute on Drug Abuse (NIDA)
First posted
Jul 8, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx headset in subjects undergoing Total Knee Arthroplasty (TKA). This study will evaluate two primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative period in the interventional, standard of care (SOC) plus RelieVRx group compared to the control, SOC group.

Conditions

  • Opioid Use
  • Arthropathy of Knee
  • Pain, Postoperative

Interventions

  • RelieVRx headsetDevice

    RelieVRx is a virtual reality therapy intended as adjunctive treatment for acute surgical pain

  • multi-modality pain managementDrug

    combination of medications may be used such as a local anesthesia, ibuprofen, acetaminophen, gabapentin, ketamine, lidocaine, and opioids

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Postoperative PainTime frame: 90 days
  2. Opioid ConsumptionTime frame: 90 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Geisinger Medical Center

    Danville, Pennsylvania

  • Geisinger Wyoming Valley Medical Center

    Wilkes-Barre, Pennsylvania

  • Geisinger South Wilkes Barre

    Wilkes-Barre, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.